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TIM-2 soaks up ferritin
 
The TIM (T cell immunoglobulin mucin) 
proteins have emerged as key regulators 
of allergic and autoimmune diseases due 
to their influence on T helper (Th)-1 and 
Th-2 responses. On page 955, Chen
and colleagues show that one member 
of this family, TIM-2, multitasks as a 
receptor for H-ferritin, a component of 
the iron storage protein ferritin.
Ferritin was not what the group 
expected to find when they launched a 
search for TIM-2 ligands. “Ferritin is not 
something immunologists think about much,” says senior author 
William Seaman. Although circulating H-ferritin had been shown to 
increase during inflammation and to bind to T and B cells, the 
consequences of these observations were largely unknown.
Chen et al. now show that although TIM-2 is most highly 
expressed in the liver, the primary iron storage organ, this protein is 
also found on splenic B cells. TIM-2 expression was particularly high 
on germinal center B cells that were actively responding to antigenic 
stimulation. Using a TIM-2 reporter cell line, they showed that a 
soluble product of activated macrophages bound to TIM-2. That 
product was H-ferritin. Binding triggered endocytosis of the 
receptor–ligand pair, suggesting that the interaction was functional.
The authors are now investigating the consequences of the ferritin–
TIM-2 interaction. A recent study showed that intracellular H-ferritin is 
required for the antiapoptotic effect of NF-
 
 
 
B activation in fibroblasts, 
prompting Seaman to speculate that H-ferritin uptake in activated 
germinal center B cells might have a similar antiapoptotic effect. 
H-ferritin (red) binds to 
TIM-2 (green) and triggers 
endocytosis of the receptor–
ligand pair (yellow).
 
NKT cells reject islets
 
Reporting on page 913, Yasunami and colleagues
show that activation of natural killer T (NKT) cells trig-
gers rejection of transplanted insulin-producing islet
cells in mice. These data suggest a possible way to avoid
the early loss of islet cells that has stymied an otherwise
promising diabetes treatment.
Insulin-dependent diabetes is caused by destruction
of the insulin-producing cells in the pancreas by CD4
 
 
 
T cells. Transplantation of islet cells is an effective way
to restore insulin production, but this therapy requires
life-long immunosuppression of the patient. And even
with immunosuppression, up to half of the transplanted
islet cells are rapidly rejected.
Early islet rejection is associated with the production
of inflammatory cytokines such as interferon-
 
 
 
 (IFN-
 
 
 
),
but the cell types involved in IFN-
 
 
 
 production and in is-
let cell rejection had not been defined. Yasunami and col-
leagues now place the blame on NKT cells. NKT cells in
mice produced IFN-
 
 
 
 in response to islet cell transplan-
tation. This triggered the production of more IFN-
 
 
 
 by
graft-infiltrating neutrophils. In the absence of NKT cells,
neutrophils or IFN-
 
 
 
, the islet cells survived.
Multiple injections with the NKT cell–activating
compound 
 
 
 
-galactosylceramide also protected against
islet rejection, consistent with recent reports suggesting
that chronic stimulation of NKT cells decreases IFN-
 
 
 
production. Thus, early inhibition of NKT cells might
help protect transplanted islet cells, even before destruc-
tive T cells are activated. 
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these cells. Rather, the immune depletion freed up activating 
cytokines, such as interleukin-7 and -15, which were being 
consumed by endogenous cells. Thus, supplementing tumor-
specific T cell transfers with activating cytokines might improve 
upon this revolutionary antitumor therapy. 
Tumor-specific T cells become fully activated in the presence 
of interleukin (IL)-7 (green dots) and IL-15 (orange diamonds).
 
Transferring tumor-specific T cells is not enough to fight disease, 
according to Gattinoni et al. on page 907, because endogenous 
cells steal necessary activating cytokines. This limits the ability of 
the transferred cells to launch an antitumor attack in mice.
Elimination of the body’s lymphocytes followed by infusion of 
tumor-specific CD8
 
 
 
 T cells has recently been shown to help 
destroy established tumors in humans. Studies in mice have 
suggested that irradiation works in two ways. The depletion of 
host cells creates empty space, which the transferred cells can fill 
by homeostatic proliferation. The depletion also rids the host of 
regulatory T (T reg) cells, which would otherwise dampen the 
function of the transferred antitumor cells.
Gattinoni and colleagues now add a new wrinkle to this story. 
They confirmed that tumor-specific T cells combated aggressive skin 
tumors more effectively in irradiated mice than in nonirradiated 
controls. To the authors’ surprise, the antitumor T cells increased to 
equivalent numbers in both mice. The cells transferred into the depleted 
mice, however, became more activated and secreted more cytokines.
The increased activation was not due to depletion of T reg 
cells, as irradiation boosted antitumor responses in mice lacking 
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